Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700036982

Trial Profile

Clinical Trials Insight: 700036982

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PSN 821 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions

Most Recent Events

  • 12 May 2009 Results reported in an OSI Pharmaceuticals media release. Results are also expected to be presented together with the second phase I trial (trial profile 700044736) at a scientific session.
  • 12 May 2009 According to an OSI Pharmaceuticals media release, data from this trial was used to support progression of PSN821 into a 14-day trial (see trial profile 700044736).
  • 12 May 2009 Status changed from recruiting to completed, according to an OSI Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top